Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5 mg once‐daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasia: an integrated analysis of four randomised, double‐blind, placebo‐controlled, clinical trials

Publisher： John Wiley & Sons Inc

E-ISSN： 1742-1241|69|12|1496-1507

ISSN： 1368-5031

Source： INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol.69, Iss.12, 2015-12, pp. : 1496-1507

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tadalafil 5 mg once daily for the treatment of Asian men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: Analyses of data pooled from three randomized, double‐blind, placebo‐controlled studies

By  

INTERNATIONAL JOURNAL OF UROLOGY, Vol. 22, Iss. 4, 2015-04 ,pp. : 378-384

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sexual function in men with LUTS due to BPH receiving TAD/FIN coadministration

By  

THE JOURNAL OF SEXUAL MEDICINE, Vol. 12, Iss. 1, 2015-01 ,pp. : 129-138

John Wiley & Sons Inc

Access to resources Recommend Favorite

Alfuzosin 10 mg Once Daily in the Management of Acute Urinary Retention of Benign Prostatic Hyperplasia: A Double-Blind, Placebo-Controlled Study

By  

Current Urology, Vol. 1, Iss. 1, 2007-09 ,pp. : 28-34

Karger

Access to resources Recommend Favorite

A Prospective, Randomized, Controlled, Multicenter Study of Naftopidil for Treatment of Male Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: 75 mg Once Daily in the Evening Compared to 25 mg Thrice Daily

By  

Urologia Internationalis, Vol. 85, Iss. 1, 2010-06 ,pp. : 80-87

Karger

Access to resources Recommend Favorite

Editorial Comment from Dr Oh‐oka to Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6‐month, randomized, double‐blind study comparing finasteride plus tadalafil with finasteride plus placebo

By  

INTERNATIONAL JOURNAL OF UROLOGY, Vol. 22, Iss. 6, 2015-06 ,pp. : 588-588

John Wiley & Sons Inc

Access to resources Recommend Favorite